Daily Roundup

XRF Scientific Posts Impressive Q2 Growth Across the Board

XRF Scientific Ltd is riding strong momentum heading into the final quarter of 2026. The company reported a 38% jump in revenue to $21.1 million in the September quarter, with profit before tax climbing 30% to $4.4 million. The growth came from broad-based strength across consumables and capital equipment sales, which generated $5.6 million and $5.9 million respectively.

The standout performer was Orbis, which saw revenue surge 66% to $2.4 million, while precious metals product sales reached $9.6 million. Perhaps most encouraging is that XRF's new India office has already turned profitable, signaling successful international expansion. The integration of the CGA acquisition is progressing well, with production expected to kick off in December—something the company expects will fuel further growth in the December quarter.

Baby Bunting Delivers Strong Results, Maintains Confident Outlook

Baby Bunting Group Ltd wrapped up FY26 on a high note, posting record sales of $556 million, up 6.5%, alongside a healthy gross margin of 41.2%. The real story, though, is what's happening in stores. The company completed 17 store refurbishments during the year, and those refreshed locations are delivering impressive results—averaging 20% sales growth compared to their pre-refurbishment performance.

The company's confidence in its strategy is reflected in its FY27 guidance, which remains unchanged. Baby Bunting expects pro forma net profit after tax between $19.0 million and $21.0 million, assuming total sales of $585 million to $600 million and comparable store sales growth of 3% to 5%. The company also announced leadership changes, with Gary Levin retiring and Richard Vincent joining the board.

PainChek Accelerates US Expansion with Sabra Deal

PainChek Limited is making serious headway in the US market. The company has expanded its footprint from two initial memory care facilities to 23 communities across five operators under its Master Services Agreement with Sabra Health Care REIT. This is a significant step up for the Australian health tech company, which is now targeting an estimated 1.2 million potential license opportunity in the assisted living and memory care space.

The near-term priority is converting these contracted arrangements into actual recurring revenue by the end of 2026, with a focus on the 808 memory care licenses currently in the pipeline. PainChek is also pursuing additional adoption opportunities throughout Sabra's broader portfolio and building relationships with other US assisted living and memory care operators.

Memphasys Hits Growth Stride with New Markets and Funding

Memphasys Ltd is firing on multiple cylinders. Quarterly invoiced revenues reached $211,000, up 41% from the previous quarter, driven by regulatory approvals that opened doors in Vietnam, Thailand, and Turkey. The company has also been busy expanding its European distribution network with new agreements in Poland, the Nordic markets, and Central Asia.

The company strengthened its position further by securing a $3.5 million funding agreement with Peters Investments, which will support manufacturing, inventory, and market expansion efforts. Adding to the momentum, Dr. Arne Schierau has joined as Director of Commercial Operations Europe. Looking ahead, Memphasys has identified a potential FDA 510(k) pathway for its Felix product and plans to engage with US regulators to clarify requirements.

Raiz Invest Discloses Tax Compliance Issues

In less positive news, Raiz Invest Limited has identified historical tax compliance issues related to tax file number and Australian Business Number withholding and reporting obligations. The issues stem from certain funds offered through the Raiz platform since its 2015 establishment.

The company has engaged WTS Australia to conduct an independent expert review and has proactively notified both the Australian Taxation Office and the Australian Securities and Investments Commission. A board-directed remediation program is underway. Importantly, customer funds remain secure, and no immediate action is required from customers as the company works through the review and regulatory engagement process.